The quality of Regeneron science has been recognized in the academic scientific community as well as through a very tangible metric: our marketed product as well as every one of our clinical candidates were discovered and validated in Regeneron's labs.

The President of Regeneron Research Laboratories is Regeneron Executive Vice President and Chief Scientific Officer George D. Yancopoulos, MD, PhD. George is the named inventor on key Regeneron patents, and he was elected to the National Academy of Sciences for the work he has done at Regeneron. Our Senior Vice President for Research and Development Sciences, Neil Stahl, PhD., was a principal inventor of our Trap technology and before joining Regeneron was a post-doctoral fellow in the laboratory of Nobel Laureate Stanley Prusiner of the University of California at San Francisco. Our Board of Directors includes three Nobelists: Alfred Gilman, MD, a co-founder of the Company; Michael Brown, MD; and Joseph Goldstein, MD, all Regental Professors at the University of Texas Southwestern Medical Center at Dallas.

At Regeneron, science is also at the very top of the organizational chart: Len Schleifer, our President and CEO, is a board-certified neurologist and Ph.D. in Pharmacology. Roy Vagelos, our Chairman, is a physician and former head of research and develeopment, and a former CEO, of Merck.

Watch George Yancopoulos, MD, Ph.D. on the Regeneron approach to science. (Video)

Listen to Neil Stahl, SVP Research and Development Sciences discuss our antibody technologies.

Jim Fandl, VP Protein Expression Sciences

Drew Murphy, VP Target Discovery

Nick Papadopoulos, VP Therapeutic Proteins

David Valenzuela, VP Functional Genomics and Chief of VelociGene Operations